{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:14:58Z","timestamp":1772259298018,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012320","name":"Otto-von-Guericke-Universit\u00e4t Magdeburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tigecycline has been used to treat patients with febrile neutropenia (FN). This study aims to analyse the effectiveness of tigecycline as salvage treatment of FN. Patients records from 09\/2004 to 04\/2019 were reviewed. Cases were eligible if fever persisted\/recurred (p\/r-FN) after 3\u00a0days of second-line treatment with a carbapenem, and were divided into three groups: switch to tigecycline (TGC group), switch to other antibiotics (OAB group), and no switch (W&amp;W group). The primary endpoint was response rate (defervescence for\u2009\u2265\u20097\u00a0days or at least until discharge); the key secondary endpoint was 30-day mortality rate. Two hundred cases from 176 patients (median 59\u00a0years; 53.5% men) treated were included, mostly acute myeloid leukaemias (61.0%). 45.5% of cases were in the TGC group (in combination with an anti-pseudomonal antibiotic, mostly ceftazidime [95.6%]); 35.5% were in the OAB and 19.0% in the W&amp;W group. There was no significant difference in response rates (TGC, 73.6%; OAB, 62.0%; W&amp;W, 78.9%; <jats:italic>p<\/jats:italic>\u2009=\u20090.12) or 30-day mortality rates (TGC, 7.7%; OAB, 7.0%; W&amp;W, 5.3%; <jats:italic>p<\/jats:italic>\u2009=\u20090.94). Tigecycline plus an anti-pseudomonal antibiotic does not improve response or 30-day mortality rate compared to other antibiotics in patients with p\/r-FN. Also, in some cases, no switch in antibiotics may be necessary at all.<\/jats:p>","DOI":"10.1007\/s00277-023-05222-5","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T16:03:07Z","timestamp":1682438587000},"page":"2607-2616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tigecycline as salvage treatment of febrile neutropenia in patients with haematological malignancies\u2014a retrospective single-centre analysis of 200 cases"],"prefix":"10.1007","volume":"102","author":[{"given":"Daniel","family":"Ge\u00dfner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-7858","authenticated-orcid":false,"given":"Mirjeta","family":"Berisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-5098","authenticated-orcid":false,"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"5222_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/bmt.2009.75","volume":"43","author":"M Trivedi","year":"2009","unstructured":"Trivedi M, Martinez S, Corringham S et al (2009) Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 43:895\u2013908. https:\/\/doi.org\/10.1038\/bmt.2009.75","journal-title":"Bone Marrow Transplant"},{"key":"5222_CR2","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/annonc\/mdu035","volume":"25","author":"JJ Vehreschild","year":"2014","unstructured":"Vehreschild JJ, B\u00f6hme A, Cornely OA et al (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol 25:1709\u20131718. https:\/\/doi.org\/10.1093\/annonc\/mdu035","journal-title":"Ann Oncol"},{"key":"5222_CR3","doi-asserted-by":"publisher","unstructured":"Paul M, Yahav D, Bivas A et al. (2010) Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev CD005197.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD005197.pub3","DOI":"10.1002\/14651858.CD005197.pub3"},{"key":"5222_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cmi.2017.03.024","volume":"23","author":"N Horita","year":"2017","unstructured":"Horita N, Shibata Y, Watanabe H et al (2017) Comparison of antipseudomonal \u03b2-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect 23:723\u2013729. https:\/\/doi.org\/10.1016\/j.cmi.2017.03.024","journal-title":"Clin Microbiol Infect"},{"key":"5222_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1086\/505393","volume":"43","author":"EJ Bow","year":"2006","unstructured":"Bow EJ, Rotstein C, Noskin GA et al (2006) A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43:447\u2013459. https:\/\/doi.org\/10.1086\/505393","journal-title":"Clin Infect Dis"},{"key":"5222_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijid.2016.01.006","volume":"44","author":"EY Nam","year":"2016","unstructured":"Nam EY, Song K-H, Kim N-H et al (2016) Differences in characteristics between first and breakthrough neutropenic fever after chemotherapy in patients with hematologic disease. Int J Infect Dis 44:4\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2016.01.006","journal-title":"Int J Infect Dis"},{"key":"5222_CR7","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96:1775\u20131792. https:\/\/doi.org\/10.1007\/s00277-017-3098-3","journal-title":"Ann Hematol"},{"key":"5222_CR8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","volume":"98","author":"M Kochanek","year":"2019","unstructured":"Kochanek M, Schalk E, von Bergwelt-Baildon M et al (2019) Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 98:1051\u20131069. https:\/\/doi.org\/10.1007\/s00277-019-03622-0","journal-title":"Ann Hematol"},{"key":"5222_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","volume":"19","author":"ND Greer","year":"2006","unstructured":"Greer ND (2006) Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 19:155\u2013161. https:\/\/doi.org\/10.1080\/08998280.2006.11928154","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"5222_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000445425","volume":"61","author":"L Xu","year":"2016","unstructured":"Xu L, Wang Y-L, Du S et al (2016) Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy 61:323\u2013330. https:\/\/doi.org\/10.1159\/000445425","journal-title":"Chemotherapy"},{"key":"5222_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, Pan Y, Shen J et al (2017) The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 16:24. https:\/\/doi.org\/10.1186\/s12941-017-0199-8","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"5222_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/MD.0b013e3181af01fc","volume":"88","author":"RF Chemaly","year":"2009","unstructured":"Chemaly RF, Hanmod SS, Jiang Y et al (2009) Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 88:211\u2013220. https:\/\/doi.org\/10.1097\/MD.0b013e3181af01fc","journal-title":"Medicine (Baltimore)"},{"key":"5222_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s15010-013-0524-x","volume":"42","author":"KS Schwab","year":"2014","unstructured":"Schwab KS, Hahn-Ast C, Heinz WJ et al (2014) Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection 42:97\u2013104. https:\/\/doi.org\/10.1007\/s15010-013-0524-x","journal-title":"Infection"},{"key":"5222_CR14","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1080\/10428194.2018.1436173","volume":"59","author":"X-P Zhou","year":"2018","unstructured":"Zhou X-P, Ye X-J, Shen J-P et al (2018) Salvage tigecycline in high risk febrile neutropenic patients with hematological malignancies: a prospective multicenter study. Leuk Lymphoma 59:2679\u20132685. https:\/\/doi.org\/10.1080\/10428194.2018.1436173","journal-title":"Leuk Lymphoma"},{"key":"5222_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(97)07061-X","volume":"350","author":"PM Arnow","year":"1997","unstructured":"Arnow PM, Flaherty JP (1997) Fever of unknown origin. Lancet 350:575\u2013580. https:\/\/doi.org\/10.1016\/S0140-6736(97)07061-X","journal-title":"Lancet"},{"key":"5222_CR16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/annonc\/mdt545","volume":"25","author":"M Hentrich","year":"2014","unstructured":"Hentrich M, Schalk E, Schmidt-Hieber M et al (2014) Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol 25:936\u2013947. https:\/\/doi.org\/10.1093\/annonc\/mdt545","journal-title":"Ann Oncol"},{"key":"5222_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B de Pauw","year":"2008","unstructured":"de Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis 46:1813\u20131821. https:\/\/doi.org\/10.1086\/588660","journal-title":"Clin Infect Dis"},{"key":"5222_CR18","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/cid\/cis270","volume":"54","author":"P Prasad","year":"2012","unstructured":"Prasad P, Sun J, Danner RL et al (2012) Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:1699\u20131709. https:\/\/doi.org\/10.1093\/cid\/cis270","journal-title":"Clin Infect Dis"},{"key":"5222_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","volume":"39","author":"F Shen","year":"2015","unstructured":"Shen F, Han Q, Xie Di et al (2015) Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis 39:25\u201333. https:\/\/doi.org\/10.1016\/j.ijid.2015.08.009","journal-title":"Int J Infect Dis"},{"key":"5222_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fmed.2019.00074","volume":"6","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Peghin M, Vena A et al (2019) Treatment of infections due to MDR Gram-negative bacteria. Front Med (Lausanne) 6:74. https:\/\/doi.org\/10.3389\/fmed.2019.00074","journal-title":"Front Med (Lausanne)"},{"key":"5222_CR21","doi-asserted-by":"publisher","unstructured":"Modemann F, H\u00e4rterich S, zur Schulze Wiesch J et al (2022) Efficacy of tigecycline as salvage therapy in multidrug-resistant febrile neutropenia in patients with acute leukemia-a single center analysis. Antibiotics (Basel) 11. https:\/\/doi.org\/10.3390\/antibiotics11020128","DOI":"10.3390\/antibiotics11020128"},{"key":"5222_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1200\/JCO.2013.51.6963","volume":"32","author":"G Bucaneve","year":"2014","unstructured":"Bucaneve G, Micozzi A, Picardi M et al (2014) Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin\/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol 32:1463\u20131471. https:\/\/doi.org\/10.1200\/JCO.2013.51.6963","journal-title":"J Clin Oncol"},{"key":"5222_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/21505594.2016.1156821","volume":"7","author":"G Gustinetti","year":"2016","unstructured":"Gustinetti G, Mikulska M (2016) Bloodstream infections in neutropenic cancer patients: a practical update. Virulence 7:280\u2013297. https:\/\/doi.org\/10.1080\/21505594.2016.1156821","journal-title":"Virulence"},{"key":"5222_CR24","doi-asserted-by":"publisher","first-page":"CD003914","DOI":"10.1002\/14651858.CD003914.pub4","volume":"6","author":"O Beyar-Katz","year":"2017","unstructured":"Beyar-Katz O, Dickstein Y, Borok S et al (2017) Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev 6:CD003914. https:\/\/doi.org\/10.1002\/14651858.CD003914.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"5222_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01700277","volume":"69","author":"H Link","year":"1994","unstructured":"Link H, Maschmeyer G, Meyer P et al (1994) Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 69:231\u2013243. https:\/\/doi.org\/10.1007\/BF01700277","journal-title":"Ann Hematol"},{"key":"5222_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/jac\/45.6.843","volume":"45","author":"Z Erjavec","year":"2000","unstructured":"Erjavec Z, de Vries-Hospers HG, Laseur M et al (2000) A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 45:843\u2013849. https:\/\/doi.org\/10.1093\/jac\/45.6.843","journal-title":"J Antimicrob Chemother"},{"key":"5222_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s15010-006-5113-9","volume":"34","author":"X Schiel","year":"2006","unstructured":"Schiel X, Link H, Maschmeyer G et al (2006) A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 34:118\u2013126. https:\/\/doi.org\/10.1007\/s15010-006-5113-9","journal-title":"Infection"},{"key":"5222_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13756-020-00729-2","volume":"9","author":"FA Niessen","year":"2020","unstructured":"Niessen FA, van Mourik MSM, Bruns AHW et al (2020) Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome. Antimicrob Resist Infect Control 9:74. https:\/\/doi.org\/10.1186\/s13756-020-00729-2","journal-title":"Antimicrob Resist Infect Control"},{"key":"5222_CR29","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.eclinm.2021.100855","volume":"35","author":"A Schauwvlieghe","year":"2021","unstructured":"Schauwvlieghe A, Dunbar A, Storme E et al (2021) Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML\/MDS (safe study): a retrospective comparative cohort study. EClinicalMedicine 35:100855. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100855","journal-title":"EClinicalMedicine"},{"key":"5222_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13756-018-0430-1","volume":"7","author":"P Yang","year":"2018","unstructured":"Yang P, Chen Y, Jiang S et al (2018) Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control 7:137. https:\/\/doi.org\/10.1186\/s13756-018-0430-1","journal-title":"Antimicrob Resist Infect Control"},{"key":"5222_CR31","doi-asserted-by":"publisher","unstructured":"Medic D, BozicCvijan B, Bajcetic M (2023) Impact of antibiotic consumption on antimicrobial resistance to invasive hospital pathogens. Antibiotics (Basel) 12. https:\/\/doi.org\/10.3390\/antibiotics12020259","DOI":"10.3390\/antibiotics12020259"},{"key":"5222_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14787210.2019.1573670","volume":"17","author":"M Schmidt-Hieber","year":"2019","unstructured":"Schmidt-Hieber M, Teschner D, Maschmeyer G et al (2019) Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert Rev Anti Infect Ther 17:983\u2013995. https:\/\/doi.org\/10.1080\/14787210.2019.1573670","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5222_CR33","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.cmi.2014.10.014","volume":"21","author":"C Orasch","year":"2015","unstructured":"Orasch C, Averbuch D, Mikulska M et al (2015) Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect 21:e25\u2013e27. https:\/\/doi.org\/10.1016\/j.cmi.2014.10.014","journal-title":"Clin Microbiol Infect"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05222-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05222-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05222-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:07:47Z","timestamp":1692706067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05222-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["5222"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05222-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study was approved by the Ethics Committee of the Medical Faculty of the Otto-von-Guericke University Magdeburg, Magdeburg, Germany (approval no. 92\/18).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given the nature of a retrospective chart review study and using routine clinical data, written informed consent was not required within the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"This retrospective chart review study was not registered within a clinical trial registry.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}